菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics Included in S&P Global Sustainability Yearbook (China Edition) for Third Consecutive Year
May 19, 2025
WuXi Biologics Included in S&P Global Sustainability Yearbook (China Edition) for Third Consecutive Year
  • S&P Global CSA score ranking in Top 1%
  • Inclusion in both Global Yearbook and China Yearbook for third consecutive year
  • Green CRDMO solutions to empower global clients on their sustainability journeys

 

Shanghai, May 19, 2025 – WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the 2025 S&P Global Sustainability Yearbook (China Edition), which was launched at the S&P Global Sustainable1 forum in Shenzhen on May 13, 2025.

 

The Sustainability Yearbook recognizes companies within their industries that have demonstrated strengths in corporate sustainability. Yearbook members are selected and their distinction levels determined based on their score in the annual S&P Global Corporate Sustainability Assessment (CSA).

 

For the third consecutive year, WuXi Biologics achieved a CSA score placing it in the Top 1% ranking, and was selected for inclusion in both the Global Sustainability Yearbook and the Sustainability Yearbook (China Edition), demonstrating its steadfast commitment to and significant advancements in driving sustainable development.

 

Dave Erbsberger and Mark Eramo, Co-Presidents of S&P Global Commodity Insights, commented, “We extend our gratitude to all the companies that participated in CSA, and are inspired by their dedication and resilience that have embraced sustainability as a core principle of current operations and forward-looking strategies. Your commitment to transparency, accountability, and innovation is vital in driving change and success.”

 

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “We are very pleased to be once again selected for the Yearbook, a reflection of our continued dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable clients worldwide to fulfill ESG commitments, and work with all stakeholders to promote responsible practices throughout the entire value chain.”

 

As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security “A list” and awarded an A- CDP Climate Change leadership-level score for two consecutive years; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

 

About WuXi Biologics

      
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

      
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

     
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

     
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

 

Contacts

    
ESG
esg@wuxibiologics.com

    
Media
PR@wuxibiologics.com